Author of

• 12853

  +

  P3.24 - Poster Session 3 - Supportive Care (ID 160)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12893

    +

    P3.24-041 - Malignant pleural mesothelioma: accumulated experience in a Brazilian tertiary hospital (ID 2800)

    09:30 - 09:30  |  Author(s): M.F.L. Tamagno
    • Abstract

    Background
    Malignant pleural mesothelioma (MPM) is the main primary malignant tumor of the pleura. It is extremely aggressive and associated with poor survival, despite multimodal treatment appropriate. Most series report the experience accumulated with the treatment of MPM in a few North American or European specialized centers. In literature, we found very little information on epidemiology and treatment of mesothelioma in Latin America. The aim of this study was to describe the experience with MPM in a tertiary university hospital in Brazil.

    Methods
    Retrospective study with patients diagnosed with MPM between December 1999 and December 2011. Diagnosis was established by histopathological analysis of the pleura. Tumor staging included CT scans of the head, thorax and abdomen. Pet Scan/PET-CT has been included since 2002. Mediastinoscopy is routinely performed since 2002. All patients were initially considered for multimodal therapy (extrapleural pleuropneumonectomy with chemotherapy and radiotherapy). The chemotherapy regimens used were cisplatin, doxorubicin, cyclophosphamide, and recently, Pemetrexed. Categorical variables were presented as percentage and continuous variables as mean and standard deviation. Kaplan-Meier estimate was used for survival analysis.

    Results
    Fifty-nine patients were included (45 M/ 14 F); mean age 49 years (13-79). Forty-five patients had epithelioid tumors (76%); 4 (7%) had sarcomathoid tumors; 8 had biphasic tumors (14%), and 2 (3%) had desmoplastic tumors. 36% of the patients had confirmed asbestos exposure. Clincal stage was Stage I, 18 patients; Stage II, 8 patients; Stage III, 21 patients: and, Stage IV, 12 patients. Therapeutic approaches were multimodal (pleuropneumonectomy extrapleural plus chemotherapy-radiotherapy) in 21 patients (36%), chemotherapy and radiotherapy in 8 (14%), radiotherapy alone in 4 (7%), chemotherapy alone in 25 (43%). Survival among patients operated was 16 + 2 months, and 15.9 + 5.7 months in the non-operated group. There was no statistical difference in survival between the groups operated and non-operated. Surgical mortality was 15%, with 40% morbidity.

    Conclusion
    The pattern of our demographic data is similar to other international series. Despite aggressive treatment, poor survival was observed in the present study.